Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept
Colorectal cancer is the second leading cause of cancer-related death worldwide. For metastatic colorectal cancer (mCRC) patients, it is recommended, as first-line treatment, chemotherapy (CT) based on doublet cytotoxic combinations of fluorouracil, leucovorin, and irinotecan (FOLFIRI) and fluorouracil, leucovorin, and oxaliplatin (FOLFOX). In addition to CT, biological (targeted agents) are indicated in the first-line treatment, unless contraindicated. In this context, most of mCRC patients are likely to progress and to change from first line to second line treatment when they develop resistance to first-line treatment options. It is in this second line setting where Aflibercept offers an alternative and effective therapeutic option, thought its specific mechanism of action for different patient’s profile: RAS mutant, RAS wild-type (wt), BRAF mutant, potentially resectable and elderly patients. In this paper, a panel of experienced oncologists specialized in the management of mCRC experts have reviewed and selected scientific evidence focused on Aflibercept as an alternative treatment.
Aflibercept; Colorectal cancer; Patient profile
González Astorga B, Salvà Ballabrera F, Aranda Aguilar E, Élez Fernández E, García-Alfonso P, González Flores E, et al. Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept. Clin Transl Oncol. 2021 Aug;23:1520–1528.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/6884
This item appears in following collections
- HVH - Articles científics 
The following license files are associated with this item: